Aclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in ApoE -/- mice

Aclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in ApoE ^-/- mice

Acta Pharm Sin B. 2024 Dec;14(12):5505-5508. doi: 10.1016/j.apsb.2024.10.008. Epub 2024 Oct 24.

Meijie Chen^{1

2}, Peter J Little³, Sudong Kong⁴, Maciej Banach⁵, Jianping Weng^{1

2}, Suowen Xu^{1

2}

¹ Department of Endocrinology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
² Anhui Provincial Key Laboratory of Metabolic Health and Panvascular Diseases, Hefei 230001, China.
³ Department of Pharmacy, Guangzhou Xinhua University, Guangzhou 510520, China.
⁴ Suzhou Biosyntech Co., Ltd., Suzhou 215300, China.
⁵ Department of Preventive Cardiology and Lipidology, Medical University of Lodz 23 (MUL), Lodz 93-338, Poland.

No abstract available

Keywords: ACLY; Aclysiran; Atherosclerosis.